Yoshiya Tanaka

54.9k total citations · 14 hit papers
1.1k papers, 30.4k citations indexed

About

Yoshiya Tanaka is a scholar working on Rheumatology, Immunology and Genetics. According to data from OpenAlex, Yoshiya Tanaka has authored 1.1k papers receiving a total of 30.4k indexed citations (citations by other indexed papers that have themselves been cited), including 667 papers in Rheumatology, 288 papers in Immunology and 246 papers in Genetics. Recurrent topics in Yoshiya Tanaka's work include Rheumatoid Arthritis Research and Therapies (428 papers), Systemic Lupus Erythematosus Research (288 papers) and Chronic Lymphocytic Leukemia Research (202 papers). Yoshiya Tanaka is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (428 papers), Systemic Lupus Erythematosus Research (288 papers) and Chronic Lymphocytic Leukemia Research (202 papers). Yoshiya Tanaka collaborates with scholars based in Japan, United States and United Kingdom. Yoshiya Tanaka's co-authors include Shingo Nakayamada, Yosuke Okada, Kazuyoshi Saito, Tsutomu Takeuchi, Stephen Shaw, Kunihiro Yamaoka, Kazuhisa Nakano, Hisashi Yamanaka, Satoshi Kubo and David Adams and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Yoshiya Tanaka

1.1k papers receiving 29.7k citations

Hit Papers

Trial of Anifrol... 1992 2026 2003 2014 2019 1993 2017 1992 2013 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Trial of Anifrolumab in Active Systemic Lupus Erythematosus
    2019 778 citations Yoshiya Tanaka et al. profile →
  2. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-lβ
    1993 774 citations Yoshiya Tanaka et al. profile →
  3. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
    2017 621 citations Peter C. Taylor, Désirée van der Heijde et al. profile →
  4. Lymphocyte interactions with endothelial cells
    1992 601 citations Yoshiya Tanaka et al. profile →
  5. Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study
    2013 456 citations Désirée van der Heijde, Yoshiya Tanaka et al. profile →
  6. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
    2018 356 citations Yoshiya Tanaka et al. profile →
  7. Janus kinase inhibitors in autoimmune diseases
    2013 354 citations Yoshiya Tanaka et al. Annals of the Rheumatic Diseases profile →
  8. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach
    2022 320 citations Yoshiya Tanaka, Shingo Nakayamada et al. profile →
  9. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
    2017 302 citations Yoshiya Tanaka, Jeffrey R. Curtis et al. Annals of the Rheumatic Diseases profile →
  10. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
    2019 260 citations Paul Emery, Yoshiya Tanaka et al. profile →
  11. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
    2020 180 citations Yoshiya Tanaka, Gerd R Burmester et al. Annals of the Rheumatic Diseases profile →
  12. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
    2021 163 citations Bernard Combe, Yoshiya Tanaka et al. Annals of the Rheumatic Diseases profile →
  13. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
    2023 124 citations Gerd R Burmester, Yoshiya Tanaka et al. RMD Open profile →
  14. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
    2023 89 citations Yoshiya Tanaka et al. profile →

Peers

Yoshiya Tanaka
Comparison fields: 5 of 162
  • Rheumatology 14.5k
  • Immunology 9.6k
  • Molecular Biology 5.7k
  • Oncology 5.4k
  • Hematology 5.2k
Replace Paul P. Tak with:
Paul P. Tak Netherlands
Ravinder N. Maini United Kingdom
Gary S. Firestein United States
René E. M. Toes Netherlands
Josef S Smolen Austria
Mark C. Genovese United States
Frank C. Arnett United States
Peter Valent Austria
Ferdinand C. Breedveld Netherlands
David Isenberg United Kingdom
Paul P. Tak Netherlands View profile →
Citations per field, relative to Yoshiya Tanaka
Yoshiya Tanaka · 1×
Citations per year, relative to Yoshiya Tanaka
Yoshiya Tanaka · 1×

Countries citing papers authored by Yoshiya Tanaka

Since Specialization
Citations

This map shows the geographic impact of Yoshiya Tanaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshiya Tanaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshiya Tanaka more than expected).

Fields of papers citing papers by Yoshiya Tanaka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshiya Tanaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshiya Tanaka. The network helps show where Yoshiya Tanaka may publish in the future.

Co-authorship network of co-authors of Yoshiya Tanaka

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshiya Tanaka. A scholar is included among the top collaborators of Yoshiya Tanaka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshiya Tanaka. Yoshiya Tanaka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Efficacy of anifrolumab in systemic lupus erythematosus patients with serological manifestations: A post hoc analysis of the Japan subgroup of the TULIP-2 trial
2025 ·Modern Rheumatology ·Yoshiya Tanaka, Tatsuya Atsumi, Masato Okada, Tomoya Miyamura, Tomonori Ishii, Susumu Nishiyama, Ryutaro Matsumura, Nobuya Hayashi, Takahiro Μatsumoto, Toshiki Yabe‐Wada, Yoshiyuki Yamaguchi, Gabriel Abreu, Catharina Lindholm, Tsutomu Takeuchi
1
2
Association of peripheral CD8+ T cell activation with disease activity and treatment resistance in systemic lupus erythematosus
2025 ·RMD Open ·(unknown), Shingo Nakayamada, Satoshi Kubo, Yusuke Miyazaki, Koshiro Sonomoto, Hiroaki Tanaka, Yoshiya Tanaka
1
3
P106 Do high rheumatoid factor titres impact response to tumour necrosis factor inhibitors? Comparison of certolizumab pegol and adalimumab in patients with rheumatoid arthritis and high titres of rheumatoid factor: a post hoc analysis of a phase 4 trial.
2024 ·Lara D. Veeken ·Josef S Smolen, Peter C. Taylor, Yoshiya Tanaka, (unknown), Bernard Lauwerys, Ricardo Machado Xavier, Jeffrey R. Curtis, Ted R. Mikuls, Michael E. Weinblatt
1
4
Effects of cyclophosphamide administration on ovarian dysfunction in pediatric patients with connective tissue diseases: A systematic scoping review
2024 ·Modern Rheumatology ·Ken‐ei Sada, Takako Miyamae, Kayoko Kaneko, (unknown), Kunihiro Ichinose, Masakazu Matsushita, Kenji Oku, (unknown), Keishi Fujio, Atsuko Murashima, Yoshiya Tanaka, Ayako Nakajima
0
5
Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses
2023 ·Rheumatology and Therapy ·Yoshiya Tanaka, Tsutomu Takeuchi, Tatsuya Atsumi, Bernard Combe, Daniel Aletaha, Toshihiko Kaise, (unknown)
2
6
A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia
2023 ·Inflammation and Regeneration ·Yoshiya Tanaka
12
7
Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan
2023 ·BMC Infectious Diseases ·Ryota Hase, Daisuke Suzuki, Cynthia de Luise, (unknown), (unknown), Takakazu Higuchi, Kayoko Katayama, Mitsuyo Kinjo, Sadao Jinno, Toshitaka Morishima, Naonobu Sugiyama, Yoshiya Tanaka, Soko Setoguchi
1
8
OA06 Clinical outcomes of filgotinib in patients with rheumatoid arthritis aged ≥65 years: a post hoc subgroup analysis of Phase 2 and 3 clinical trials and ongoing long-term extensions
2023 ·Lara D. Veeken ·Maya H Buch, Bernard Combe, José A. Gómez‐Puerta, Roberto Caporali, Jacques‐Eric Gottenberg, (unknown), (unknown), (unknown), Katrien Van Beneden, Daniel Aletaha, Gerd R Burmester, René Westhovens, Yoshiya Tanaka
1
9
Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis
2023 ·The Journal of Clinical Pharmacology ·Tsutomu Takeuchi, Yukihiro Chino, Yoko Mano, (unknown), Yuri Sato, Saeko Uchida, Yoshiya Tanaka
2
10
Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis
2023 ·Rheumatology and Therapy ·Paul Emery, Yoshiya Tanaka, Vivian P. Bykerk, T. Huizinga, Gustavo Citera, Clifton O. Bingham, Subhashis Banerjee, Benjamin P. Soule, Marleen Nys, Seán Connolly, (unknown), (unknown), Robert Wong, Kuan‐Hsiang Gary Huang, R. Fleischmann
6
11
The management of women of childbearing age with rheumatoid arthritis: an expert report
2023 ·Expert Review of Clinical Immunology ·Yoshiya Tanaka, Atsuko Murashima, Tatsuya Atsumi, Hiroaki Dobashi, Yohko Murakawa, Shigeki Momohara, (unknown), Shinji Tanigaki, Shintaro Makino, Shigeru Saito
3
12
Systemic lupus erythematosus with repeated protein-losing enteropathy resulting from different pathological conditions: a case report
2020 ·Modern Rheumatology Case Reports ·(unknown), Kazuhisa Nakano, Ippei Miyagawa, Masanobu Ueno, Yoshiya Tanaka
2
13
Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial
2019 ·Annals of the Rheumatic Diseases ·Tsutomu Takeuchi, Yoshiya Tanaka, Satoshi Soen, Hisashi Yamanaka, Toshiyuki Yoneda, Sakae Tanaka, (unknown), Naoki Okubo, Harry K. Genant, Désirée van der Heijde
108
14
A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period
2017 ·Modern Rheumatology ·Atsushi Ogata, Yoshiya Tanaka, Tomonori Ishii, (unknown), (unknown), (unknown), (unknown)
15
15
Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study
2017 ·Advances in Therapy ·Tsutomu Takeuchi, Ryo Nakajima, Shuichi Komatsu, (unknown), Tomohiro Nakamura, Naoki Agata, Ataru Igarashi, Toshiro Tango, Yoshiya Tanaka
20
16
Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
2016 ·Arthritis Research & Therapy ·Hisashi Yamanaka, Yoshiya Tanaka, Tsutomu Takeuchi, Naonobu Sugiyama, (unknown), Shigeyuki Toyoizumi, Yosuke Morishima, Tomohiro Hirose, Samuel H. Zwillich
124
17
A Multi-Biomarker Disease Activity (Vectra DA) Algorithm Score for Rheumatoid Arthritis Predicts Radiographic Progression in the BeSt Study
2011 ·Data Archiving and Networked Services (DANS) ·C.F. Allaart, Linda Dirven, Shintaro Hirata, (unknown), (unknown), David Chernoff, G. Cavet, Michael Centola, (unknown), Yoshiya Tanaka, T. Huizinga, (unknown)
1
18
Induction of expression of MHC‐class‐II antigen on human thyroid carcinoma by wild‐type p53
1998 ·International Journal of Cancer ·Kazuya Zeki, Yoshiya Tanaka, Isao Morimoto, Yasuharu Nishimura, Akinori Kimura, Uki Yamashita, Sumiya Eto
3
19
Induction of expression of MHC-class-II antigen on human thyroid carcinoma by wild-type p53
1998 ·International Journal of Cancer ·Kazuya Zeki, Yoshiya Tanaka, Isao Morimoto, Yasuharu Nishimura, Akinori Kimura, Uki Yamashita, Sumiya Eto
12
20
Constitutive up-regulation of integrin-mediated adhesion of tumor-infiltrating lymphocytes to osteoblasts and bone marrow-derived stromal cells.
1998 ·PubMed ·Yoshiya Tanaka, Shinichiro Mine, Takeshi Hanagiri, Toru Hiraga, I Morimoto, Carl G. Figdor, Yvette van Kooyk, Hiroki Ozawa, Tetsuya Nakamura, Kosei Yasumoto, S Eto
34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul P. Tak Breakdown of academic impact, for papers by Ravinder N. Maini Breakdown of academic impact, for papers by Gary S. Firestein Breakdown of academic impact, for papers by René E. M. Toes Breakdown of academic impact, for papers by Josef S Smolen Breakdown of academic impact, for papers by Mark C. Genovese Breakdown of academic impact, for papers by Frank C. Arnett Breakdown of academic impact, for papers by Peter Valent Breakdown of academic impact, for papers by Ferdinand C. Breedveld Breakdown of academic impact, for papers by David Isenberg
Rankless by CCL
2026